Christy Oliger
Director/Board Member at KARYOPHARM THERAPEUTICS INC.
Net worth: 113 476 $ as of 2024-05-30
Profile
Christy J.
Oliger is an Independent Director at Karyopharm Therapeutics, Inc., Replimune Group, Inc., LAVA Therapeutics NV, and Vera Therapeutics, Inc. She previously served as an Independent Director at Sierra Oncology, Inc., Reata Pharmaceuticals, Inc., and Rayzebio, Inc. She also held the position of Senior Vice President-Oncology Business Unit at Genentech, Inc. Ms. Oliger completed her undergraduate degree at the University of California, Santa Barbara.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-06-06 | 2,987 ( 0.01% ) | 113 476 $ | 2024-05-30 | |
REPLIMUNE GROUP, INC.
-.--% | 2024-03-31 | 0 ( -.--% ) | - $ | 2024-05-30 |
| 2024-05-28 | 0 ( -.--% ) | - $ | 2024-05-30 |
Christy Oliger active positions
| Companies | Position | Start |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Director/Board Member | 2020-08-27 |
| REPLIMUNE GROUP, INC. | Director/Board Member | 2021-11-30 |
| LAVA THERAPEUTICS N.V. | Director/Board Member | 2023-03-08 |
| VERA THERAPEUTICS, INC. | Director/Board Member | 2024-06-06 |
Former positions of Christy Oliger
| Companies | Position | End |
|---|---|---|
| RAYZEBIO, INC. | Director/Board Member | 2024-02-25 |
| REATA PHARMACEUTICALS, INC. | Director/Board Member | 2023-09-25 |
| SIERRA ONCOLOGY, INC. | Director/Board Member | 2022-06-30 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2020-06-30 |
Training of Christy Oliger
| University of California, Santa Barbara | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| LAVA THERAPEUTICS N.V. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| VERA THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Stock Market
- Insiders
- Christy Oliger
